评论
打印
A new study suggests that people infected with COVID-19 in the past may receive protection against some kinds of common colds.
一项新的研究表明，过去感染过新冠病毒的人可能会对某些常见的感冒病毒产生免疫力。
COVID-19 is one of several coronaviruses known to affect humans.
新冠病毒是已知的几种会影响人类的冠状病毒之一。
The new research found that past COVID-19 infections can lower the risk of getting colds caused by other coronaviruses.
新的研究发现，过去感染过新冠病毒可以降低感染其他冠状病毒引起感冒的风险。
Studies have shown coronaviruses account for about one in five colds.
研究表明，冠状病毒约占感冒的五分之一。
Researchers involved in the study say their results could support future efforts to improve COVID-19 vaccines or develop new ones.
参与这项研究的研究人员表示，他们的研究结果可以支持未来改进 COVID-19 疫苗或开发新疫苗的工作。
The study examined COVID-19 tests from more than 4,900 people who sought medical care between November 2020 and October 2021.
该研究对2020年11月至2021年10月期间就医的4900多人进行了COVID-19检测。
It showed that people previously infected with COVID-19 had a 50 percent lower chance of having a coronavirus-caused cold than those who were fully vaccinated and had not gotten COVID-19.
它表明，之前感染过新冠病毒的人，比那些完全接种了疫苗但没有感染过新冠病毒的人，患冠状病毒引起的感冒的几率低50%。
The research recently appeared in the publication Science Translational Medicine. The lead writer of the study was Dr. Manish Sagar.
这项研究最近发表在《科学转化医学》杂志上，主要作者是马尼什·萨加尔博士。
He is an infectious disease specialist at Boston Medical Center and a professor at Boston University in Massachusetts.
他是波士顿医疗中心的传染病专家，也是马萨诸塞州波士顿大学的教授。
Sagar told the Associated Press, “We think there’s going to be a future outbreak of a coronavirus.”
萨加尔告诉美联社，“我们认为冠状病毒未来会爆发。”
He said current coronavirus vaccines might be improved if researchers could copy some of the immune reactions “provided by natural infection.”
他说，如果研究人员能够复制 “自然感染所提供的 ”一些免疫反应，那么目前的冠状病毒疫苗可能会得到改进。
Researchers linked the protection against coronavirus-caused colds to virus-killing cell reactions for two viral proteins.
研究人员将针对冠状病毒引起的感冒的保护作用与针对两种病毒蛋白的病毒杀伤细胞反应联系起来。
These proteins are not currently used in most vaccines.
这些蛋白质目前并未用于大多数疫苗中。
But the researchers have proposed adding them in the future.
但是，研究人员已经提议在未来添加。
Sagar said this development may lead to future vaccines that could target not only current coronaviruses, but also new ones that might appear.
萨加尔表示，这一进展可能会导致未来的疫苗不仅能够针对当前的冠状病毒，还能够针对可能出现的新病毒。
Dr. Wesley Long is a pathologist at Houston Methodist in Texas. He was not involved in the study.
韦斯利·朗博士是德克萨斯州休斯顿卫理公会医院的病理学家。他没有参与这项研究。
Long noted that the findings should not be seen as a weakness of current vaccines.
朗指出，这些发现不应被视为当前疫苗的弱点。
These vaccines target a so-called “spike protein” contained in the SARS-CoV-2 virus that causes COVID-19.
这些疫苗针对的是导致新冠肺炎的新冠病毒中所含的一种所谓的“刺突蛋白”。
Long said those vaccines are “still your best defense against severe COVID-19 infection, hospitalization and death.”
朗说，这些疫苗“仍然是预防严重的COVID-19感染、住院和死亡的最佳方法。”
But Long added that new targets could be added to existing vaccines in an effort to “cross-protect against multiple viruses.”
但朗补充说，可以在现有疫苗中添加新的靶点，以 “交叉保护，抵御多种病毒”。
This process, he said, could result in wider immunity from a single vaccine.
他补充道，这个过程可能会使单一疫苗产生更广泛的免疫力。
I’m Bryan Lynn.
我是布莱恩·林恩。
